We can't find the internet
Attempting to reconnect
25253.1 PFLS-LS
25253.1 PFLS-LS
Résumé
Intermediate scale manufacturing and in vivo therapeutic assessment of a promising drug candidate for the treatment of GM1-gangliosidosis
Textes supplémentaires
Abstract
GM1-gangliosidosis is a rare orphan genetic disease caused by mutated forms of the lysosomal enzyme beta-galactosidase. DO-1 is a chaperone drug candidate that has been shown to rescue the defective enzyme activity in ex vivo patient cells. The current project proposes to perform critical steps in the preclinical development of DO-1, consisting in the set-up of its intermediate scale production route and the assessment of its therapeutic efficacy in a mouse model.
Participants
Julie Charollais-Thoenig
Wirtschaftspartner
charollais@dorphan.com
Dorphan SA CHE-407.871.618 Julie Charollais-Thoenig Chemin de l'Eglise 7 1066 Epalinges VD CH
Roger Marti
Kontaktperson
roger.marti@hefr.ch
HEIA-FR Haute Ecole d'ingénierie et d'archi de Fribourg Roger Marti Boulevard de Pérolles 80 1700 Fribourg FR CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2016-10-31
- Date de fin
- 2018-03-31
- Coûts totaux approuvés
- CHF 309800.00
- Section
- 20 Förderbereich Life Sciences
- Domaine politique NABS
- Industrielle Produktivität und Technologie
Disciplines de recherche
- T115 Medical technology 100.0%